As RESI prepares for its second landing on MaRS on April 4th, the team at Life Science Nation is proud to announce the RESI investor panel agenda. With three tracks of panel and workshop content, RESI will feature a wealth of speakers representing all categories of life science investors, from family offices to VCs and angels to big pharma. These panels are a must-see for any fundraising entrepreneur in the sector...
On April 4th, the Redefining Early Stage Investments (RESI) Conference will be held at the MaRS Discovery District for the second time. RESI is a full day partnering event that allows early-stage life science, med tech, and digital health companies meet and develop relationships with investors and strategic partners all within the heart of Canada's healthcare innovation hub...
Orphan diseases present a unique opportunity for an investor as there are several advantages from a regulatory standpoint given the shorter development timeline and exclusivity possibility as well as the ability to truly impact patient's lives that have no treatment options. On the flipside, they have challenges primarily due to the size of the patient population and usually require a somewhat unique business model and marketing strategy to be a viable opportunity.
In our first and largest RESI conference of 2017, held for the third time at the Marines Memorial Club and Hotel during the JP Morgan healthcare week, a varied group of investors explore some of these challenges and opportunities with funding and commercializing rare disease drugs and share their firsthand experience in this space...
Life Science Investor Mandates
On April 4th, the Redefining Early Stage Investments (RESI) Conference will be held at the MaRS Discovery District for the second time. RESI is a full day partnering event that allows early-stage life science, med tech, and digital health companies meet and develop relationships with investors and strategic partners all within the heart of Canada's healthcare innovation hub...
Orphan diseases present a unique opportunity for an investor as there are several advantages from a regulatory standpoint given the shorter development timeline and exclusivity possibility as well as the ability to truly impact patient's lives that have no treatment options. On the flipside, they have challenges primarily due to the size of the patient population and usually require a somewhat unique business model and marketing strategy to be a viable opportunity.
